Products 1661854-97-2
CAS 1661854-97-2 appears in our catalog under these names: Tas6417, 95%, TAS6417/ 99.19% (existing batch purity), TAS6417, TAS 6417, 2-Propenamide, N-[(8S)-4-amino-8,9-dihydro-6-methyl-5-(3-quinolinyl)pyrimido[5,4-b]indolizin-8-yl]-, 97%, 97%. Offered by: Combi-blocks, TargetMol, GLPBio, Biosynth, Chemat. Available pack sizes: 100mg, 1mg, 2mg, 5mg, 10mg, 25mg, 50mg, 500mg.
Zipalertinib is a member of the class of acrylamides that is (8S)-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizine-4,8-diamine in which the amino group at position 8S is substituted by an acryloyl group. It a covalent epidermal growth factor receptor inhibitor that targets exon 20 insertion mutations. It has a role as an antineoplastic agent, an apoptosis inducer and an epidermal growth factor receptor antagonist. It is a secondary carboxamide, a member of acrylamides, a member of quinolines, an organic heterotricyclic compound, an aromatic amine and a primary amino compound.
Source: ChEBI
| Molecular formula | C23H20N6O |
|---|---|
| Molecular weight | 396.4 g/mol |
| IUPAC name | N-[(8S)-4-amino-6-methyl-5-quinolin-3-yl-8,9-dihydropyrimido[5,4-b]indolizin-8-yl]prop-2-enamide |
| InChIKey | MKCYPWYURWOKST-INIZCTEOSA-N |
| SMILES | CC1=C[C@@H](CN2C1=C(C3=C(N=CN=C32)N)C4=CC5=CC=CC=C5N=C4)NC(=O)C=C |
Computed by PubChem (NCBI)
Synonyms:
Zipalertinib, Cln 081, Pan-EGFR Inhibitor CLN-081, Mutation-specific EGFR TKI TAS6417, EGFR Mutant-specific Inhibitor CLN-081, Pan-mutation-selective EGFR Inhibitor CLN-081, Pan-mutation-selective EGFR Tyrosine Kinase Inhibitor CLN-081, Zipalertinib [INN], zipalertinibum, Zipalertinib [WHO-DD]